BLCO Stock Recent News
BLCO LATEST HEADLINES
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Amended and Restated Director Appointment and Nomination Agreement, dated as of June 21, 2022, by and among the company and Mr. Carl C. Icahn and certain of his affiliates, terminated pursuant to its terms when the Icahn group's net long position in the common shares of Bausch + Lomb's parent company, B.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that members of its management team will participate in two investor conferences in September: J.P. Morgan European Leveraged Finance Conference September 3, 2025, London, U.K. Morgan Stanley Global Healthcare Conference September 8, 2025, 7:45 a.m. ET, New York, NY Executive Vice President and Chief Financial O.
Bausch + Lomb Corporation (NYSE:BLCO ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Brenton L. Saunders - CEO & Chairman George Gadkowski - Corporate Participant Osama A.
Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.13 per share a year ago.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2025 financial results. “Our continued growth speaks to the breadth and depth of our portfolio and is driven by a mix of hero products and a steady stream of new introductions around the world,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our robust pipeline represents the future of.
ACHC, BLCO and BBCP have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2025.
COMP, EKTAY and BLCO have been added to the Zacks Rank #5 (Strong Sell) List on July 24, 2025.
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.